| Description |
In the increasingly demanding drug discovery environment, the value of an optimally designed, focused library cannot be overstated. Are you sure you are having the best in place?
The shift from drug discovery methods based on HTS and large compound collections to the use of focused compound libraries has significantly improved the pace and productivity of drug discovery and efficient lead findings.
Still crucial questions remain unsolved and are topics for discussion: How to find the ideal size of the library to assure diversity while staying focused? Is fragment-based screening a possibility to fasten up the discovery process?
• Learn how to maintain the balance between quantity and quality when designing and selecting compounds for the library
• Hear about enhanced screening methods such as fragment-based screening to reduce complexity in the screens
• Explore how to combine internal compound synthesis with external compound acquisition to build up a comprehensive compound collection
• Hear case studies on target classed libraries such as kinase inhibitor or GCPR libraries to understand for which areas of research they are most appropriate
• Discuss how to improve the hit-to-lead process to increase the outcome of promising candidates
High-level speakers from international leading companies such as Sanofi-Aventis, AstraZeneca, Novartis, Roche, Merz, Astex, Schering and many more are invited to present cutting-edge case studies and discuss challenges of focused compound libraries.
|
|
